Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Completed · Phase 1/Phase 2
Conditions studied: Leukemia, Myelodysplastic Syndromes
In brief
RATIONALE: Chemotherapy, such as fludarabine and thiotepa, and radiation therapy may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow. Giving healthy stem cells from a donor whose blood closely resembles the patient's blood will help the patient's bone marrow make new stem cells that become red blood cells, white blood cells, and platelets. PURPOSE: This phase I/II trial is studying the side effects of total-body irradiation, fludarabine, and thiotepa and to see how well they work in treating young patients who are undergoing a donor stem cell transplant for hematologic cancer.
Key facts
- Study ID
- NCT00112567
- Run by
- Fred Hutchinson Cancer Center
- People needed
- 20
- Starts
- 2003-04-01
- Expected to finish
- 2007-07-01
- Last updated by the study team
- 2010-09-21
Who can join
Age: any, up to 20. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
- Seattle Cancer Care Alliance — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.